



Cyclization of Fungal Nonribosomal Peptides by a Terminal Condensation-Like Domain

Citation

Gao, Xue, Stuart W. Haynes, Brian D. Ames, Peng Wang, Linda P. Vien, Christopher T. Walsh, and Yi Tang. 2012. Cyclization of fungal nonribosomal peptides by a terminal condensation-like domain. *Nature chemical biology* 8(10): 823-830.

Published version

<https://doi.org/10.1038/nchembio.1047>

Link

<http://nrs.harvard.edu/urn-3:HUL.InstRepos:11238938>

Terms of use

This article was downloaded from Harvard University's DASH repository, and is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at

<https://harvardwiki.atlassian.net/wiki/external/NGY5NDE4ZjgzNTc5NDQzMGIzZWZhMGFIOWI2M2EwYTg>

Accessibility

<https://accessibility.huit.harvard.edu/digital-accessibility-policy>

Share Your Story

The Harvard community has made this article openly available.
Please share how this access benefits you. [Submit a story](#)

Published in final edited form as:

Nat Chem Biol. 2012 October ; 8(10): 823–830. doi:10.1038/nchembio.1047.

Cyclization of Fungal Nonribosomal Peptides by a Terminal Condensation-Like Domain

Xue Gao¹, Stuart W. Haynes², Brian D. Ames², Peng Wang¹, Linda P. Vien¹, Christopher T. Walsh^{2,*}, and Yi Tang^{1,3,*}

¹Department of Chemical and Biomolecular Engineering, University of California Los Angeles, 420 Westwood Plaza, Los Angeles, CA 90095

²Department of Biological Chemistry & Molecular Pharmacology, Harvard Medical School, 240 Longwood Avenue, Boston, MA 02115

³Department of Chemistry and Biochemistry, University of California Los Angeles, 420 Westwood Plaza, Los Angeles, CA 90095

Abstract

Cyclization of linear peptidyl precursors produced by nonribosomal peptide synthetases (NRPSs) is an important step in the biosynthesis of bioactive cyclic peptides. Whereas bacterial NRPSs use thioesterase (TE) domains to perform the cyclization, fungal NRPSs have apparently evolved to use a different enzymatic route. In verified fungal NRPSs that produce macrocyclic peptides, each megasynthetase terminates with a condensation-like (C_T) domain that may perform the macrocyclization reaction. To probe the role of such a C_T domain, we reconstituted the activities of the *Penicillium aethiopicum* trimodular NRPS TqaA in *Saccharomyces cerevisiae* and *in vitro*. Together with a reconstituted bimodular NRPS AnaPS, we dissected the cyclization steps of TqaA in transforming the linear anthranilate-D-tryptophan-L-alanyl tripeptide into fumiquinazoline F. Extensive biochemical and mutational studies confirmed the essential role of the C_T domain in catalyzing cyclization in a thiolation domain-dependent fashion. Our work provided evidence of a likely universal macrocyclization strategy employed by fungal NRPSs.

Cyclic nonribosomal peptides (NRPs) from filamentous fungi represent a group of pharmaceutically important natural products, including the immunosuppressive cyclosporine A and the antifungal family of lipopeptides represented by echinocandin B^{1,2}. Biosynthesis of the linear precursors of these molecules by their corresponding nonribosomal peptide synthetases (NRPSs) parallels that of bacterial NRPs, such as the well-studied tyrocidine A and gramicidin^{3,4}. Following the sequential addition of each amino acid catalyzed by a NRPS module, which consists minimally of condensation (C), adenylation (A) and thiolation (T) domains, cyclization and product release take place through nucleophilic attack on the thioester carbonyl by a free amine from either the *N*-terminus or side chain of the peptide^{3,5}. Given the importance of cyclization to the biological activities of these

*Correspondence: yitang@ucla.edu, christopher_walsh@hms.harvard.edu.

Contributions

X.G., S.W.H., C.T.W. and Y.T. developed the hypothesis and designed the study. S.W.H. performed the synthesis of all the chemicals in this study. X.G. and P.W. performed molecular cloning. X.G., P.W. and L.P.V. performed the heterologous protein expression and purification. X.G. and B.D.A. performed *in vitro* and *in vivo* characterization of the megasynthetases. All authors analyzed and discussed the results. X.G., C.T.W. and Y. T. prepared the manuscript.

Competing financial interests

The authors declare no competing financial interests.

molecules, understanding the enzymatic basis of this final step in NRPs biosynthesis is a significant goal from both mechanistic and biocatalytic perspectives^{6,7}.

Whereas bacterial NRPSs use thioesterase (TE) domains to perform the cyclization, fungal NRPSs have apparently evolved to use a complementary strategy^{7–9}. From the verified fungal NRPS gene clusters to date, none of the NRPSs associated with cyclic NRPs contain terminal TE domains, nor a free-standing TE-like domain encoded in the vicinity of the gene cluster¹⁰. Instead, TE domains have only been found to be associated with hydrolyzed peptide products such as the linear ACV tripeptide synthesized by the ACV synthetase⁵. In macrocyclic fungal NRPs such as cyclosporine A, aureobasidin A, apicidin and ferrichrome A, each corresponding NRPS terminates with a condensation-like domain (C_T)^{11–15} (Fig. 1). Similarly, in smaller polycyclic NRP alkaloids such as tryptoquialanine, the NRP core is assembled by a NRPS (TqaA) that terminates with a C_T domain¹⁶ (Fig. 1). In the NRPS paradigm, C domains are canonically categorized to catalyze the formation of a peptide bond between the growing peptidyl- $S-T_n$ and the activated aminoacyl- $S-T_{n+1}$ using an active site histidine as the general base^{17,18}. The active site serves as a scaffold to bring together the donor and acceptor aminoacyl thiolation domains¹⁹. Therefore, it is surprising that the C_T domain (a subset of C domains) can be recruited by fungal NRPS to perform the equivalent reaction of a TE domain, which relies on a serine residue for nucleophilic catalysis⁷. Understanding the role of the C_T domain in fungal NRPSs will have broad implications, as many of the cryptic NRPSs discovered from fungal genome sequences terminate with a C_T domain^{9,10}.

To investigate the role of the C_T domain and the cyclization of fungal NRPs, we focused on the trimodular TqaA, which has been shown genetically to be involved in the biosynthesis of the tricyclic peptidyl alkaloid fumiquinazoline F **1** (Fig. 2) in *Penicillium aethiopicum*¹⁶. TqaA is functionally equivalent to Af12080 from the fumiquinazoline A biosynthetic pathway in *Aspergillus fumigatus*²⁰. The three modules (C^*AT_1 - CAT_2E - CAT_3-C_T) of TqaA are proposed to activate anthranilate (Ant), L-tryptophan and L-alanine to yield the tripeptide Ant-D-Trp-L-Ala **3** attached to the last T domain ($3-S-T_3$)^{16,21} (Fig. 2). Formation of the pyrazinoquinazoline ring and release of **1** require two cyclization steps, hypothesized to be catalyzed by the C_T domain (Fig. 2). Interestingly, the domain organization and substrate selectivity of the first two modules of TqaA are identical to those of AnaPS (C^*AT_1 - CAT_2E), which is involved in the synthesis of the 3-indolylmethyl-3,4-dihydrobenzo-1,4-diazepine-2,5-dione precursor *R*-**2** of acetylaszonalenin in *Neosartorya fischeri*²². Intriguingly, AnaPS terminates with an epimerization (E) domain rather than a C_T domain, although it is known that E and C domains share sequence and structural similarities¹⁸.

Here we present the complete *in vitro* reconstitution of the trimodular TqaA expressed from *Saccharomyces cerevisiae*, allowing biochemical investigation of the cyclization steps. The functions of AnaPS are studied in parallel to compare and contrast the cyclization steps between the two NRPSs. We show that the C_T domain of TqaA is indispensable for the cyclization of **1** and requires protein-protein interactions with the T_3 domain for catalysis.

RESULTS

In vitro Reconstitution of TqaA and AnaPS Activities

To pinpoint the domains that are involved in the cyclization of linear peptides, we first attempted to reconstitute the activities of the NRPSs *in vitro*. This is particularly challenging for the megasynthetases such as TqaA (450 kDa) as no NRPS with more than two modules has been successfully expressed in an active form to date. Towards this end, *Saccharomyces cerevisiae* 2- μ m episomal vectors encoding *tqaA* (12 kb) and *anaPS* (7 kb) under the control

of the ADH2 promoter were constructed using a modified yeast-based homologous recombination method²³ (Supplementary Results, Supplementary Fig. 1). Both *N*-FLAG-tagged enzymes were expressed using the engineered *S. cerevisiae* BJ5464-NpgA, which contained multiple vacuolar protease knockouts and a chromosomally integrated copy of the *Aspergillus nidulans* *npgA* gene that encoded a phosphopantetheinyl transferase²⁴. The co-expression of NpgA in BJ5464 is required for the conversion of *apo* thiolation domains into the phosphopantetheinylated *holo* forms²⁵. This strain had been successfully used as a host for heterologous reconstitution of large fungal polyketide synthases^{24,26}. To verify functional expression of the NRPSs, small molecule metabolites in the three-day growth media were extracted with ethyl acetate and analyzed using LC-MS. Compared to the untransformed yeast strain, BJ5464-NpgA expressing TqaA and AnaPS produced **1** and *R*-2 at ~2 mg/L, respectively (Fig. 3a). Following this confirmation of NRPS activities, full length TqaA and AnaPS (264 kDa) were purified to near homogeneity by using anti-FLAG antibody affinity chromatography followed by gel filtration to final yields of ~1 mg l⁻¹ (Supplementary Figures 2 and 3).

After the affinity purification step, activities of the A domains of NRPSs were assessed using amino acid-dependent γ -³²P-ATP-PP_i exchange assay (Supplementary Methods and Fig. 3b)²⁷. TqaA specifically activated the three building blocks Ant, L-Trp and L-Ala over the respective D-amino acids or aryl acids. Similarly, AnaPS A domains activated Ant and L-Trp. Both NRPSs also activated aryl substrates such as benzoate (by TqaA), salicylate (by AnaPS) and 1, 2-dihydroxylbenzoate (DHB, by AnaPS), pointing to the relaxed substrate specificities of the Ant-specific A domains. The preference displayed by both NRPSs toward L-Trp over D-Trp strongly points to an active epimerization (E) domain in the second module of both NRPSs.

Complete reconstitution of TqaA and AnaPS activities was then performed by adding the amino acid building blocks (2 mM each) and ATP (6 mM) to each of the purified enzymes (10 μ M). The reaction mixtures were incubated at room temperature for 12 hours, extracted with ethyl acetate and analyzed by LC-MS (Fig. 3c). **1** (obtained from the Δ *tqaH* strain of *P. aethiopicum*¹⁶) and chemically synthesized *R*-2 were used as authentic standards (Supplementary Methods). In the TqaA assay, **1** was synthesized as the single peptidyl product; no dipeptidyl or other tripeptidyl products could be detected through LC and selective ion monitoring by MS. A HPLC-based time course study revealed that the reaction proceeds with initial product formation rate of 0.40 ± 0.014 min⁻¹ (Supplementary Fig. 4a). Similarly in the AnaPS assay, the only product detected was the 6, 7-cyclic dipeptide *R*-2 with an initial product formation rate of 1.47 ± 0.047 min⁻¹ (Supplementary Fig. 4c).

Reconstitution of the synthesis of **1** and *R*-2 using purified TqaA and AnaPS, respectively, showed that each NRPS was sufficient to construct and cyclize the linear peptide into the multicyclic products. The proposed cyclization mechanisms are shown in Fig. 2. In the simpler case of AnaPS, attack of the Ant free amine on the thioester carbonyl of Ant-D-Trp-*S*-T₂ (D-4-*S*-T₂) yields *R*-2. However in TqaA, this reaction is apparently suppressed in favor of chain elongation by the third module to yield 3-*S*-T₃. Two cyclization routes to **1** are possible starting from 3-*S*-T₃ (Fig. 2b). In route A, attack of the Ant amine on the thioester carbonyl yields a 10-membered macrocyclic intermediate, which can undergo a bridging amide bond cyclization and dehydration to yield **1**; in route B, the D-Trp amide serves as the initial nucleophile in attacking the thioester 3-*S*-T₃ to yield the diketopiperazine (DKP) intermediate. Subsequent intramolecular attack by the Ant amine and dehydration completes the pyrazinoquinazoline scaffold.

Formation of *R*-2 can be spontaneous

To investigate the cyclization step of AnaPS, we chemically synthesized Ant-D-Trp-*S*-*N*-acetylcysteamine (D-4-SNAC). Under enzymatic assay conditions, D-4-SNAC was cyclized to yield *R*-2 with an initial product formation rate of 0.1 min⁻¹ (Supplementary Fig. 5a). The significant rate of spontaneous cyclization suggested that product release from AnaPS could be uncatalyzed. The spontaneous cyclization rate, however, was at least fourteen-fold slower than that of D-4-*S*-T₂, hinting that domains in AnaPS may promote a conformation of the dipeptide that was more favorable for formation of the seven-membered ring. Adding AnaPS to D-4-SNAC, however, did not increase the cyclization rate, suggesting that the proposed templating effect may only take place with an enzyme-tethered dipeptide (Supplementary Fig. 5b).

The enantiomer Ant-L-Trp-SNAC (L-4-SNAC) was also prepared synthetically, and an identical rate of cyclization to *S*-2 was observed (Supplementary Methods and Supplementary Fig. 5c). The availability of both *R*-2 and *S*-2 as standards allowed us to examine the enantiopurity of the product released by AnaPS using chiral HPLC (Fig. 4a). Under assay conditions, only enantiomerically pure *R*-2 was detected in the organic extract, suggesting AnaPS exerts strict product stereochemical control. To probe the importance of the epimerization step catalyzed by the E domain on *R*-2 formation, we generated a point mutant of AnaPS (AnaPS-E⁰) in which the second His in the H²⁰⁵⁹HxxxDx catalytic motif was mutated to Ala (Supplementary Fig. 3)²⁸. As expected, AnaPS-E⁰ no longer produces *R*-2 when Ant and L-Trp are added. Instead, we observed the appearance of *S*-2 at only ~1% of the level of *R*-2 produced by the wild type AnaPS (Fig. 4a, note the sizes of *R*-2 and *S*-2 peaks in traces i and ii are not drawn to scale). Based on the very low level of *S*-2 production by AnaPS-E⁰, two possible control mechanisms can be proposed. In the first model, AnaPS could suppress the rapid cyclization of L-4-*S*-T₂ until epimerization to D-4-*S*-T₂ takes place. The chiral environment in the E domain active site may position the Ant amine away from the thioester carbonyl. In this model, epimerization of the Trp residue took place on the dipeptidyl-*S*-T₂, which was proposed to be favored over the epimerization of the free aminoacyl thioester due to stabilization of the carbanion intermediate through acylation of the nitrogen in the peptide bond²⁹. In the second model, formation of L-4-*S*-T₂ by the C₂ domain was strongly disfavored in the absence of epimerization, therefore requiring the E domain to function on L-Trp-*S*-T₂ prior to condensation with Ant-*S*-T₁. Intriguingly, D-Trp could be activated and transferred to the T₂ domain of AnaPS (Supplementary Fig. 6). However, AnaPS did not produce any product in the presence of Ant and D-Trp, suggesting that L-Trp was required for condensation to take place and thus providing evidence against the second model. Further attempts to distinguish between the two models through excision of the E domain from AnaPS were not successful because no soluble protein was recovered.

Given that the D-4-*S*-T₂ intermediate can rapidly cyclize spontaneously, it is intriguing how formation of *R*-2 can be effectively suppressed by TqaA following formation of this dipeptidyl intermediate, especially given that the first two modules of TqaA and AnaPS appear to be functionally equivalent. Efforts to express modules 1 and 2 of TqaA as a standalone enzyme, or replace them with AnaPS resulted in insoluble proteins, despite the high sequence similarity. An initial hypothesis was that the subsequent condensation with L-Ala catalyzed by C₃ of TqaA was sufficiently rapid to sequester the reactive dipeptide. However, mutation of the C₃ active site general base His²⁶⁵⁸ to Ala not only abolished the synthesis of **1**, but also failed to yield any trace of *R*-2. Similarly, performing the TqaA *in vitro* assay with only Ant and L-Trp also did not produce *R*-2 (Supplementary Fig. 7). Hence, it was reasonable to propose that the C₃ active site, in particular through the donor

peptidyl entrance site, can structurally protect the D-4 moiety and can prevent cyclization and offloading of the intermediate as *R*-2.

Formation of Fumiquinazoline F requires the C_T domain

Having probed the formation of *R*-2 by AnaPS, we next examined the cyclization of 3-*S*-T₃ into **1** by TqaA. This was a particularly intriguing transformation as a simple linear tripeptide was morphed into the 6, 6, 6 pyrazinoquinazoline tricyclic ring system. First, to understand the stability of the tripeptidyl thioester, we synthesized 3-SNAC starting from the free acid **3** (Supplementary Methods). In contrast to 4-SNAC, 3-SNAC was remarkably stable under assay conditions, and levels of the hydrolysis product **3** only reached a noticeable level after approximately 8 hours. No cyclized products such as **1** can be observed after more than 24 hours of incubation (Supplementary Fig. 5d). Therefore, whereas formation of *R*-2 can be spontaneous, formation of **1** definitely required enzyme catalysis. The C_T domain in TqaA was the most likely domain that could catalyze this reaction. Phylogenetic analysis showed that fungal C_T domains group separately from the canonical chain-extending C domains (Supplementary Figures 8 and 9). Based on bioinformatic analysis, the percentage of fungal NRPSs incorporating a C_T domain varied from 60 to 90%, depending on the genome analyzed (Supplementary Table 2).

Multiple sequence alignment of the active sites of different sequenced C_T domains revealed variations in the first His residue of the highly conserved HHxxxDxxS motif of C domains (S³⁷⁶⁵HSQWDGVS³⁷⁷³ in TqaA)¹⁷ (Supplementary Fig. 10). The His proposed to be acting as the general base is conserved in all C_T domains. To probe the role of the C_T domain in pyrazinoquinazoline formation, we constructed the following mutants of TqaA: S³⁷⁶⁵A and S³⁷⁶⁵H to probe the role of the nonconserved serine, and H³⁷⁶⁶A to probe the role of the putative active site base. Among them, TqaA H³⁷⁶⁶A was expressed and purified from BJ5464-NpgA for *in vitro* assay (Supplementary Fig. 3). Whereas the S³⁷⁶⁵ mutants maintained production of **1** at levels comparable to that of the wild type in *S. cerevisiae*, the H³⁷⁶⁶A mutant failed to yield any detectable peptidyl product both in *S. cerevisiae* and *in vitro* using the purified enzyme (Supplementary Fig. 11). To exclude the possibility that an inactivated C_T domain may structurally prevent the cyclization of 3-*S*-T₃, a truncated version of TqaA without the C_T domain (TqaA-ΔC_T, 400 kDa) was constructed, expressed and assayed. In parallel, the standalone C_T domain was expressed and purified from *Escherichia coli* (Supplementary Fig. 3). When assayed *in vitro*, whereas TqaA-ΔC_T failed to produce any detectable amount of **1**, complementation of TqaA-ΔC_T with equimolar amounts of C_T *in trans* restored the synthesis of **1**, albeit to a lesser extent compared to full length TqaA (Fig. 4b). The lower level of **1** may be a result of inefficient *in trans* protein-protein interactions. Indeed, addition of twenty-fold molar excess of C_T to the reaction mixture dramatically increased the production of **1**, resulting in levels comparable to that observed when using intact TqaA. In contrast, *in trans* addition of a C_T⁰ mutant in which the catalytic His was mutated to Ala failed to restore the synthesis of **1**. With all of the inactivated mutants described above we did not detect any hydrolyzed **3** free acid in the reaction mixture, suggesting that the NRPS-tethered tripeptide was remarkably resistant to hydrolysis compared to 3-SNAC (Supplementary Fig. 5d). Collectively, these results unequivocally proved the essential role of the terminal C_T domain in formation of the final product **1**.

C_T cyclization activity requires T domain

Having confirmed the catalytic nature of the C_T domain, we next assayed the standalone C_T in the cyclization reaction. Cyclizing TE domains from bacterial NRPSs can cyclize small molecule thioester mimics of the linear precursors^{6,30}. However, when 3-SNAC or 3-*S*-CoA was used as a substrate for TqaA C_T, no cyclized **1** was detected after prolonged incubation

(Supplementary Methods and Supplementary Fig. 12). To prepare the authentic 3-*S*-T₃ substrate for C_T, the *apo* form of standalone T₃ was expressed from *E. coli* (Supplementary Fig. 3) and modified *in vitro* in the presence of 3-*S*-CoA and the broadly specific phosphopantetheinyl transferase Sfp³¹. MALDI-TOF mass analysis confirmed the near quantitative conversion from the *apo* form (molecular weight 11197) to 3-*S*-T₃ (molecular weight 11913) (Supplementary Fig. 13). In the absence of the C_T domain, slow hydrolysis of this thioester to **3** was observed. When the wild type C_T was combined with 3-*S*-T₃, a new peak was observed during HPLC that corresponds to **1**, and no hydrolysis was detected (Fig. 4c), confirming the importance of the T domain in facilitating C_T functions. Adding the mutant C_T⁰ did not yield any cyclized product, but partially suppressed the hydrolysis of 3-*S*-T₃ possibly due to the templating effect of the C_T active site. The kinetic parameters of the cyclizing reaction were measured as shown in Supplementary Fig. 14. The *k*_{cat} of the reaction was determined to be 0.82 ± 0.053 min⁻¹ and *K*_m of C_T for 3-*S*-T₃ was 1.1 ± 0.12 mM. **1** can also be formed in a one-pot reaction containing *apo*-T₃, 3-*S*-CoA, Sfp and C_T, in which the phosphopantetheinyl modification took place *in situ*. When Ant-L-Trp-L-Ala-*S*-CoA (*epi*-3-*S*-CoA) was used to prepare *epi*-3-*S*-T₃, the C_T domain also efficiently cyclized the diastereomeric peptide into the corresponding 14-*epi*-fumiquinazoline **5**, indicating relaxed substrate specificity of the cyclization reaction towards the tripeptide (Fig. 2 and Fig. 4c).

To examine the T domain substrate specificity of C_T, we also prepared noncognate T domains 3-*S*-T_{ApdA} and 3-*S*-T_{LovF}, which correspond to the ACP domains of the fungal PKS-NPRS ApdA and PKS LovF, respectively^{26,32}. Both T_{ApdA} and T_{LovF} share low sequence identity/similarity (~20%/60%) with TqaA T₃. T_{ApdA} naturally interacts with a downstream C domain in ApdA and the tethered polyketide intermediate is condensed with a tyrosine residue, while T_{LovF} does not interact with any C-like domain. TqaA C_T was able to recognize 3-*S*-T_{ApdA} to produce **1**, albeit with <10% efficiency compared to 3-*S*-T₃ (Supplementary Fig. 15) and was accompanied by hydrolysis of 3-*S*-T_{ApdA}. Only background hydrolysis of 3-*S*-T_{ApdA} was observed when T_{LovF} was used as the peptidyl carrier. Therefore, the protein-protein interactions between C_T and the T domains are selective, and may rely on T domain sequence elements that are unique for recognition by C domains. Noncognate T domains such as T_{LovF} that do not interact with downstream C-like domains likely do not possess these elements and are not substrates of the C_T domain.

Cyclization Mechanism of C_T

In an attempt to differentiate between the two alternate mechanisms of cyclization to the observed 6, 6, 6 tricyclic compound **1** (Fig. 2b), we examined the propensity of analogues of the natural Ant-Trp-Ala system to undergo C_T mediated cyclization (Fig. 4d and Supplementary Fig. 16). Using the standalone T₃ domain of TqaA and Sfp as loading catalyst we generated three tripeptidyl-T₃ analogues specifically designed to disfavor either the macrocyclization (pathway A in Fig. 2b) or DKP formation (pathway B in Fig. 2b). From Ant-L-*N*-Me-Trp-L-Ala-*S*-T₃, a released product with mass [M+H]⁺ of 391 (exact mass = 391.1765) consistent with the proposed *N*-methyl-10 membered macrolactam (Fig. 5 and Supplementary Fig. 17) was observed. Further cyclization of this intermediate was strongly disfavored (both sterically and by the formation of a quaternary cationic product) by the tertiary nitrogen which would be required to act as nucleophile. Nonetheless, a mass consistent with this cationic product resulting from the transannular attack of the tertiary amine actually was observed as a very minor product. The formation of this product despite the steric and electronic barriers to its formation (as stated above) lends support to the geometry of this proposed macrocycle favoring the required orientation for transannular cyclization. It is worth noting that the same mass would also be consistent with the formation of a cation *N*-Me-Trp derived DKP, but such a product would likely be very

unstable and be subject to rapid hydrolysis to form Ant-*N*-Me-Trp-Ala free acid, which was not detected. Conversely salicylate-D-Trp-L-Ala-*S*-T₃ or benzoate-D-Trp-L-Ala-*S*-T₃, which would be expected to disfavor/prevent macrocyclization (but not interfere with DKP formation), gave no products corresponding to the mass of the dehydrated tripeptide (corresponding to either DKP or macrocycle isomers) (Fig. 5). Although the mechanism of C_T mediated cyclization remains difficult to elucidate due to the reactivity of proposed intermediates, taken together these data support a route where macrolactamization precedes DKP formation in the formation of these C_T mediated 6, 6, 6 tricyclic scaffolds.

DISCUSSION

In this work, we have reconstituted the activities of two fungal NRPSs, the trimodular TqaA and the bimodular AnaPS that make tricyclic and bicyclic heterocyclic scaffolds, respectively. The choice of the two NRPSs was based on the observation that while the first two modules of TqaA are identical to AnaPS, addition of the third module dramatically altered the structures of the resulting polycyclic NRP alkaloid products. The difference in the cyclization pattern is likely due to the precise control of the reactive dipeptide D-4 intermediate, and the use of a C-like cyclization domain that regioselectively directs the intramolecular attack of the Ant amine nucleophile. While bimodular NRPSs from both bacteria and fungi have been reconstituted previously^{33–35}, the sheer size of NRPSs such as TqaA complicated soluble expression and functional reconstitution. The use of *S. cerevisiae* BJ5464-NpgA allowed high-yield heterologous expression and full manifestation of TqaA activities. The successful use of this strain in affording intact NRPSs should open the door to the functional analysis of the expanding collection of fungal NRPSs available through different sequencing efforts.

The use of the cyclic aromatic β-amino acid anthranilate as the chain initiation building block by AnaPS and TqaA is key for the generation of the 6, 7 fused bicyclic *R*-2 (AnaPS) and the fused 6, 6, 6 tricyclic **1** (TqaA) scaffolds. The planar 1, 3 disposition of the amino group and the carbonyl in the anthranil unit efficiently sets up the D-4-*S*-T₂ intermediate for cyclization on the second module of AnaPS. This facile cyclization, demonstrable in the nonenzymatic thioester model, sets the unusual 6, 7 bicyclic ring system that is subsequently elaborated by prenylation and acetylation in the acetylaszonalenin pathway²². Notably this same 6, 7-scaffold would be an unwanted derailment product in the trimodular TqaA. Such premature release is seemingly suppressed by the action of the C-domain that results in the generation of a 3-*S*-T₃ species. Chain release at this point mediated by C_T instead creates the tricyclic scaffold of **1**. The NH₂ of the anthranil unit is again acting as an internal nucleophile on a thioester but this does not happen appreciably nonenzymatically. Clearly, the use of anthranilate as a NRPS starter unit enables construction of distinct patterns of nitrogen-containing bicyclic and tricyclic scaffolds at the core of related families of fungal peptidyl alkaloids. In the case of the fumiquinazolines, these can be further elaborated into highly constrained architectures with up to seven fused rings in the mature scaffold³⁶. Thus, understanding how anthranilate gets activated, elongated, and cyclized on fungal NRPS assembly lines offers prospects for diversification of peptidyl alkaloid scaffolds.

Fungal NRPSs have several different strategies for product release following completion of peptide elongation^{7,8}. TE domains have been found to be responsible for the hydrolysis of full length peptidyl-NRPS adducts as in the ACV synthetase that is responsible for the production of the ACV peptide precursor to penicillin⁵. NADPH-dependent reductive (R) domains have been found to be associated with the family of peptaibol linear peptides, in which the C-terminal thioester is reduced to an amino alcohol³⁷. R and R-like domains are also found at the C-termini of PKS-NRPS hybrid megasynthetases which can catalyze reductive chain release or Dieckmann cyclization, respectively^{38,39}. However, based on

recent genome sequencing efforts, a majority (60–90%) of the NRPSs found in filamentous fungi terminate with a C_T domain (Supplementary Table 2). Previous sequencing of individual gene clusters has also revealed that C_T domains are associated with macrocyclic and/or polycyclic NRPSs. In this work, using the pyrazinoquinazoline **1** as an example, we demonstrated that the C_T domain in the TqaA NRPS was responsible for the cyclization of the highly stable tripeptide **3-S-T₃**. The cyclization function of C_T is likely to be general for other fungal NRPSs such as those shown in Fig. 1, including cyclosporine synthetase SimA¹¹. Macrocyclization C_T domains may also play a role in the biosynthesis of cyclohexadepsipeptide destruxins in the insect pathogenic fungi *Metarhizium robertsii*⁴⁰ and in NRPSs from filamentous cyanobacteria, as illustrated in the apratoxin biosynthetic gene cluster from *Lyngbya bouillonii*⁴¹. C_T domains have also been proposed to be involved in the cyclization via ester bond formation during the biosynthesis of bacterial polyketide-peptidyl hybrid FK520 and rapamycin^{42,43}. However, those C_T domains fall into a different group by phylogenetic analysis (Supplementary Fig. 9).

The use of a C_T domain to heterocyclize or macrocyclize peptidyl products is a different strategy from the canonical TE domains found in bacterial NRPSs. The C_T domains and TE domains have completely different folds and utilize different mechanisms to catalyze the same reaction. In the TE domain where a catalytic triad is present, the peptidyl intermediate is first transferred to the active site serine, followed by intramolecular nucleophilic attack on the oxyester to complete cyclization⁷. In contrast, as seen for canonical C domains that catalyze peptide bond formation, no covalent adduct with the enzyme is expected to be formed during C_T catalyzed cyclization⁵. Instead, the catalytic histidine deprotonates the amine nucleophile, thus facilitating its attack on the thioester carbonyl to cyclize and release the product in one step. Another significant mechanistic difference is the requirement for a specific T domain partner in the C_T domain catalyzed cyclization reaction. We showed here that only peptide substrates tethered to the natural T domain partner of the C_T domain are efficiently recognized, while peptidyl-SNAC or peptidyl-CoA substrates are not recognized. This contrasts with most TE domains where small-molecule mimics of the peptidyl-thioester can be used to probe the cyclization functions^{6,30}. One exception is the fengycin TE that involves direct interactions with the upstream T domains to mediate the cyclization⁴⁴. The interactions between T and C_T domains likely evolved from the interactions between upstream T and downstream C domains during peptide elongation, which facilitate the unidirectional delivery of the peptidyl substrate in a productive conformation to the donor site. This specific interaction may be advantageous to prevent spontaneous cyclization of the peptide from backbone amides or side chain amines. C_T domains also appear to advantageously eliminate the competing hydrolysis reaction, which is observed *in vitro* with bacterial TE domains where hydrolysis of the oxyester intermediate can take place in competition with the cyclization reaction⁷. This is especially prevalent under *in vitro* conditions where a standalone TE is used. In contrast, the templating nature of the C_T highly disfavors hydrolysis as illustrated in the reconstitution assay using **3-S-T₃**.

METHODS

Cloning, expression and purification of TqaA and AnaPS

Cloning of the intact gene into the expression vector was performed using the modified yeast-based homologous recombination method²³. The *tqaA* gene was divided into 4 pieces (P1 ~ P4) with a maximum size of ~4.5 kb. The only intron (577 – 661 bp) of the *tqaA* gene within P1 was removed by RT-PCR. P2 to P4 were PCR amplified from the genomic DNA of *P. aethiopicum*. Each successive piece was designed to overlap (35 – 40 bp) with the two flanking ones, and the 5′-end of P1 and 3′-end of P4 overlap with the expression vector. The vector fragment was generated by digesting pXW55 (an expression vector with an

engineered FLAG tag on *N*-terminus and 6×His-tag on C-terminus) with *Spe*I and *Pml*I²⁶. The individual *tqaA* pieces (1 µg per piece) as well as the vector (~ 0.5 µg) were co-transformed using the EasyComp™ Transformation Kit (Invitrogen) into *S. cerevisiae* strain BJ5464-NpgA to allow assembly of the entire gene *in vivo*. The assembled plasmid was miniprep from *S. cerevisiae* using yeast plasmid miniprep II kit (Zymo) and further verified by PCR and restriction enzyme digestion. The cloning procedure for the *anaPS* gene was the same as described for *tqaA*. The verified plasmid containing intact *tqaA* or *anaPS* gene was transformed into *S. cerevisiae* strain BJ5464-NpgA for protein expression. For 1 L of yeast culture, the cells were grown at 28 °C in YPD media with 1% dextrose for 72 hours. For detailed protein purification procedure, refer to Supplementary Methods. FLAG-tagged TqaA and AnaPS proteins were purified by using ANTI-FLAG® M1 Agarose Affinity Gel (Sigma-Aldrich). The cleared cell lysate was directly applied onto a column packed with ANTI-FLAG Agarose Affinity Gel. TqaA/AnaPS protein was eluted with buffer containing 0.5 mg ml⁻¹ FLAG peptide. For the cloning and expression procedures for other proteins mentioned in this paper, see Supplementary Methods.

Synthesis of peptidyl-SNAC, peptidyl-S-CoA and peptidyl-S-T substrates

Syntheses of peptidyl-SNACs and peptidyl-S-CoAs are described in the Supplementary Methods. Loading reactions of *apo*-T₃ or other ACP domains were carried out in 50 mM MES buffer (pH 6.8) and initiated by addition of 5 µM Sfp. After 2 hours, 3-S-T₃ was buffer-exchanged into MilliQ water using an Amicon Ultra 10 MWCO 10,000 Daltons, followed by identification with MALDI-TOF MS and used for kinetics assays.

In vitro assays

To test the *in vitro* activities of TqaA, AnaPS or other mutant proteins, 2 mM of each amino acid building block, 6 mM ATP, 4 mM MgSO₄ and 10 µM of purified proteins were combined in 50 mM Tris-HCl buffer (pH 7.5) to a total volume of 100 µl. After 12 hours incubation, reactions were quenched and extracted with 1 ml of ethyl acetate. The organic layer was dried and re-dissolved in methanol for LC-MS analyses. For kinetic characterization of the C_T domain towards 3-S-T₃, the concentration of the C_T domain was kept constant at 2 µM. Initial velocities were determined at various 3-S-T₃ concentrations ranging from 20 to 1053 µM. Samples were analyzed on a Shimadzu 2010 EV liquid chromatography mass spectrometer using positive and negative electrospray ionization and a Phenomenex Luna 5 µm, 2.0 mm × 100 mm C18 reverse-phase column. Samples were separated on a linear gradient of 5 to 95% CH₃CN in water (0.1% formic acid) for 30 min at a flow rate of 0.1 ml min⁻¹ followed by isocratic 95% CH₃CN in water (0.1% formic acid) for 15 min.

Other general materials, methods and procedures. See Supplementary Methods.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments


This work is supported in part by National Institutes of Health Grant GM20011 (to C.T.W.), F32GM090475 (to B.D.A.) and 1R01GM092217 (to Y.T.). Wei Xu is thanked for assistance with MALDI-TOF mass analysis and providing the both ApdA and LovF ACP domains. Yen-Ting Lai is thanked for assistance with gel filtration FPLC.

References

1. Bierer BE, Hollander G, Fruman D, Burakoff SJ. Cyclosporine A and FK506: molecular mechanisms of immunosuppression and probes for transplantation biology. *Curr Opin Immunol.* 1993; 5:763–773. [PubMed: 7694595]
2. Chen SC, Slavin MA, Sorrell TC. Echinocandin antifungal drugs in fungal infections: a comparison. *Drugs.* 2011; 71:11–41. [PubMed: 21175238]
3. Sieber SA, Marahiel MA. Molecular mechanisms underlying nonribosomal peptide synthesis: approaches to new antibiotics. *Chem Rev.* 2005; 105:715–738. [PubMed: 15700962]
4. Sattely ES, Fischbach MA, Walsh CT. Total biosynthesis: *in vitro* reconstitution of polyketide and nonribosomal peptide pathways. *Nat Prod Rep.* 2008; 25:757–793. [PubMed: 18663394]
5. Fischbach MA, Walsh CT. Assembly-line enzymology for polyketide and nonribosomal peptide antibiotics: logic, machinery, and mechanisms. *Chem Rev.* 2006; 106:3468–3496. [PubMed: 16895337]
6. Kohli RM, Walsh CT, Burkart MD. Biomimetic synthesis and optimization of cyclic peptide antibiotics. *Nature.* 2002; 418:658–661. [PubMed: 12167866]
7. Kopp F, Marahiel MA. Macrocyclization strategies in polyketide and nonribosomal peptide biosynthesis. *Nat Prod Rep.* 2007; 24:735–749. [PubMed: 17653357]
8. Du LC, Lou LL. PKS and NRPS release mechanisms. *Nat Prod Rep.* 2010; 27:255–278. [PubMed: 20111804]
9. Von Doehren H. A survey of nonribosomal peptide synthetase (NRPS) genes in *Aspergillus nidulans*. *Fungal Genet Biol.* 2009; 46:S45–S52. [PubMed: 18804170]
10. Eisfeld, K. Physiology and Genetics. 1. Vol. 15. Springer; Berlin Heidelberg: 2009. Non-Ribosomal Peptide Synthetases of Fungi; p. 315-316.
11. Lawen A, Zocher R. Cyclosporin synthetase. The most complex peptide synthesizing multienzyme polypeptide so far described. *J Biol Chem.* 1990; 265:11355–11360. [PubMed: 2358465]
12. Jin JM, et al. Functional characterization and manipulation of the apicidin biosynthetic pathway in *Fusarium semitectum*. *Mol Microbiol.* 2010; 76:456–466. [PubMed: 20233305]
13. Slightom JL, Metzger BR, Luu HT, Elhammer AP. Cloning and molecular characterization of the gene encoding the aureobasidin A biosynthesis complex in *Aureobasidium pullulans* BP-1938. *Gene.* 2009; 431:67–79. [PubMed: 19084058]
14. Winterberg B, et al. Elucidation of the complete ferrichrome A biosynthetic pathway in *Ustilago maydis*. *Mol Microbiol.* 2010; 75:1260–1271. [PubMed: 20070524]
15. Zocher R, et al. Biosynthesis of cyclosporin A: partial purification and properties of a multifunctional enzyme from *Tolypocladium inflatum*. *Biochemistry.* 1986; 25:550–553. [PubMed: 3955013]
16. Gao X, et al. Fungal indole alkaloid biosynthesis: genetic and biochemical investigation of the tryptotoqualanine pathway in *Penicillium aethiopicum*. *J Am Chem Soc.* 2011; 133:2729–2741. [PubMed: 21299212]
17. Bergendahl V, Linne U, Marahiel MA. Mutational analysis of the C-domain in nonribosomal peptide synthesis. *Eur J Biochem.* 2002; 269:620–629. [PubMed: 11856321]
18. Keating TA, Marshall CG, Walsh CT, Keating AE. The structure of VibH represents nonribosomal peptide synthetase condensation, cyclization and epimerization domains. *Nat Struct Biol.* 2002; 9:522–526. [PubMed: 12055621]
19. Samel SA, Schoenafinger G, Knappe TA, Marahiel MA, Essen LO. Structural and functional insights into a peptide bond-forming bidomain from a nonribosomal peptide synthetase. *Structure.* 2007; 15:781–792. [PubMed: 17637339]
20. Ames BD, Walsh CT. Anthranilate-activating modules from fungal nonribosomal peptide assembly lines. *Biochemistry.* 2010; 49:3351–3365. [PubMed: 20225828]
21. Ames BD, Liu X, Walsh CT. Enzymatic processing of fumiquinazoline F: a tandem oxidative-acylation strategy for the generation of multicyclic scaffolds in fungal indole alkaloid biosynthesis. *Biochemistry.* 2010; 49:8564–8576. [PubMed: 20804163]

22. Yin WB, Grundmann A, Cheng J, Li SM. Acetylazonalenin biosynthesis in *Neosartorya fischeri* Identification of the biosynthetic gene cluster by genomic mining and functional proof of the genes by biochemical investigation. *J Biol Chem*. 2009; 284:100–109. [PubMed: 19001367]
23. Shao Z, Zhao H, Zhao H. DNA assembler, an *in vivo* genetic method for rapid construction of biochemical pathways. *Nucleic Acids Res*. 2009; 37:e16. [PubMed: 19074487]
24. Ma SM, et al. Complete reconstitution of a highly reducing iterative polyketide synthase. *Science*. 2009; 326:589–592. [PubMed: 19900898]
25. Mootz HD, Schorgendorfer K, Marahiel MA. Functional characterization of 4' phosphopantetheinyl transferase genes of bacterial and fungal origin by complementation of *Saccharomyces cerevisiae* lys5. *Fems Microbiol Lett*. 2002; 213:51–57. [PubMed: 12127488]
26. Xu W, Cai XL, Jung ME, Tang Y. Analysis of intact and dissected fungal polyketide synthase-nonribosomal peptide synthetase *in vitro* and in *Saccharomyces cerevisiae*. *J Am Chem Soc*. 2010; 132:13604–13607. [PubMed: 20828130]
27. Rusnak F, Sakaitani M, Drueckhammer D, Reichert J, Walsh CT. Biosynthesis of the *Escherichia coli* siderophore enterobactin: sequence of the *entf* gene, expression and purification of *entf*, and analysis of covalent phosphopantetheine. *Biochemistry*. 1991; 30:2916–2927. 28. [PubMed: 1826089]
28. Stachelhaus T, Walsh CT. Mutational analysis of the epimerization domain in the initiation module PheATE of gramicidin S synthetase. *Biochemistry*. 2000; 39:5775–5787. [PubMed: 10801328]
29. Linne U, Marahiel MA. Control of directionality in nonribosomal peptide synthesis: role of the condensation domain in preventing misinitiation and timing of epimerization. *Biochemistry*. 2000; 39:10439–10447. [PubMed: 10956034]
30. Sieber SA, Tao JH, Walsh CT, Marahiel MA. Peptidyl thiophenols as substrates for nonribosomal peptide cyclases. *Angew Chem Int Ed Engl*. 2004; 43:493–498. [PubMed: 14735544]
31. Quadri LEN, et al. Characterization of Sfp, a *Bacillus subtilis* phosphopantetheinyl transferase for peptidyl carrier protein domains in peptide synthetases. *Biochemistry*. 1998; 37:1585–1595. [PubMed: 9484229]
32. Xie X, Meehan MJ, Xu W, Dorrestein PC, Tang Y. Acyltransferase mediated polyketide release from a fungal megasynthase. *J Am Chem Soc*. 2009; 131:8388–8389. [PubMed: 19530726]
33. Balibar CJ, Walsh CT. GliP, a multimodular nonribosomal peptide synthetase in *Aspergillus fumigatus*, makes the diketopiperazine scaffold of gliotoxin. *Biochemistry*. 2006; 45:15029–15038. [PubMed: 17154540]
34. Keating TA, Miller DA, Walsh CT. Expression, purification, and characterization of HMWP2, a 229 kDa, six domain protein subunit of yersiniabactin synthetase. *Biochemistry*. 2000; 39:4729–4739. [PubMed: 10769129]
35. Lee JH, Evans BS, Li GY, Kelleher NL, van der Donk WA. *In vitro* characterization of a heterologously expressed nonribosomal peptide synthetase involved in phosphinothricin tripeptide biosynthesis. *Biochemistry*. 2009; 48:5054–5056. [PubMed: 19432442]
36. Ames BD, et al. Complexity generation in fungal peptidyl alkaloid biosynthesis: oxidation of fumiquinazoline A to the heptacyclic hemiaminal fumiquinazoline C by the flavoenzyme Af12070 from *Aspergillus fumigatus*. *Biochemistry*. 2011; 50:8756–8769. [PubMed: 21899262]
37. Daniel JFD, Rodrigues E. Peptaibols of *Trichoderma*. *Nat Prod Rep*. 2007; 24:1128–1141. [PubMed: 17898900]
38. Liu XY, Walsh CT. Cyclopiazonic acid biosynthesis in *Aspergillus* sp.: characterization of a reductase-like R* domain in cyclopiazonate synthetase that forms and releases *cyclo*-acetoacetyl-L-tryptophan. *Biochemistry*. 2009; 48:8746–8757. [PubMed: 19663400]
39. Sims JW, Schmidt EW. Thioesterase-like role for fungal PKS-NRPS hybrid reductive domains. *J Am Chem Soc*. 2008; 130:11149–11155. [PubMed: 18652469]
40. Wang B, Kang Q, Lu Y, Bai L, Wang C. Unveiling the biosynthetic puzzle of destruxins in *Metarhizium* species. *Proc Natl Acad Sci USA*. 2012; 109:1287–1292. [PubMed: 22232661]
41. Grindberg RV, et al. Single cell genome amplification accelerates identification of the apratoxin biosynthetic pathway from a complex microbial assemblage. *PLoS One*. 2011; 6(4):e18565. [PubMed: 21533272]

42. Gatto GJ, McLoughlin SM, Kelleher NL, Walsh CT. Elucidating the substrate specificity and condensation domain activity of FkbP, the FK520 pipecolate-incorporating enzyme. *Biochemistry*. 2005; 44:5993–6002. [PubMed: 15835888]
43. Schwecke T, et al. The biosynthetic gene-cluster for the polyketide immunosuppressant rapamycin. *Proc Natl Acad Sci USA*. 1995; 92:7839–7843. [PubMed: 7644502]
44. Sieber SA, Walsh CT, Marahiel MA. Loading peptidyl-coenzyme A onto peptidyl carrier proteins: a novel approach in characterizing macrocyclization by thioesterase domains. *J Am Chem Soc*. 2003; 125:10862–10866. [PubMed: 12952465]

**Figure 1.**

Fungal nonribosomal peptide synthetases (NRPSs) that are terminated with a C-like domain. **(a)** Representative NRPSs: cyclosporine NRPS SimA, aureobasidin A NRPS Aba1, apicidin NRPS Aps1, ferrichrome A NRPS Fer3, tryptoquialanine NRPS TqaA, acetylaszonalenin NRPS AnaPS. Domain abbreviations: C: condensation domain; A: adenylation domain; T: thiolation domain; E: epimerization domain; C*: truncated and presumably inactive C domain; C_T: Terminal C-like domain. **(b)** Representatives structures of final products synthesized by the clusters in part **a**.




Figure 2. Proposed AnaPS (**a**) and TqaA (**b**) cyclization mechanisms. (Domain abbreviations: C: condensation domain; A: adenylation domain; T: thiolation domain; E: epimerization domain; C*: truncated and presumably inactive C domain; C_T: Terminal C-like domain).





Figure 3.

Characterization of TqaA and AnaPS. **(a)** *in vivo* reconstitution of TqaA and AnaPS. Shown are HPLC analysis ($\lambda = 272$ nm) of metabolites extracted from 3-day cultures of i) untransformed BJ5464-NpgA; ii) BJ5464-NpgA expressing TqaA; iii) BJ5464-NpgA expressing AnaPS. **(b)** amino acid-dependent ATP-PP_i exchange assays with AnaPS and TqaA. Abbreviations: benzoate (Benz); 1, 2-dihydroxybenzoate (DHB). **(c)** *in vitro* reconstitution of TqaA and AnaPS. Shown are HPLC analysis ($\lambda = 272$ nm) of compounds from extraction of reaction mixtures containing 2 mM of the amino acid building blocks and i) no enzyme; ii) 10 μ M TqaA; iii) 10 μ M AnaPS; iv) standard of **1**; and v) standard of *R*-2.

**Figure 4.**

The cyclization steps of TqaA and AnaPS. (a) chiral HPLC followed by selected mass ion monitoring (m/z 305) of *R*-2 or *S*-2 synthesized from AnaPS (trace ii) and AnaPS- E^0 (trace i). Standards of *R*-2 (trace iv) and *S*-2 (trace iii) are shown for comparison. The intensities of peaks are not drawn to scale. (b) confirmation of TqaA C_T domain function. All assays contained 10 μ M of the NRPS (TqaA or TqaA- ΔC_T) and 2 mM of each amino acid. Standalone C_T or C_T^0 was added *in trans*. The traces shown are selected mass ion monitoring (m/z 358) of compounds extracted from reactions containing i) wild type TqaA; ii) TqaA- ΔC_T ; iii) TqaA- ΔC_T with 10 μ M C_T ; iv) 10 μ M TqaA- ΔC_T with 200 μ M C_T ; and v) TqaA- ΔC_T with 200 μ M C_T^0 . (c) confirmation of C_T cyclization activity using preloaded peptidyl thiolation domain. 3-*S*- T_3 or *epi*-3-*S*- T_3 (200 μ M) was used to assay the production of 1 or 5, respectively. Traces shown are HPLC analyses ($\lambda = 272$ nm) of i) 3-*S*- T_3 without C_T ; ii) standard of 1; iii) 3-*S*- T_3 with 20 μ M C_T ; iv) *epi*-3-*S*- T_3 with 20 μ M C_T . (d) Analogues of 3 were used to probe the cyclization route of C_T domain. 200 μ M tripeptide analogues were used to react with C_T (20 μ M). Traces i) and ii) are Ant-L-*N*-Me-Trp-L-Ala-*S*- T_3 without and with C_T , respectively; Trace iii) and iv) are salicylate-D-Trp-L-Ala-*S*- T_3 without and with C_T , respectively; Trace v) and vi) are benzoate-D-Trp-L-Ala-*S*- T_3 without and with C_T , respectively.




Figure 5. Probing the possible TqaA C_T domain cyclization mechanisms using analogues of the tripeptide 3.